Penumbra Inc logo

PENPenumbra Inc

NYSE · Healthcare · Medical Devices

$323.89

+$1.31 (+0.41%)

Penumbra Inc (PEN) is a medical devices company listed on NYSE. It is led by Adam Elsesser J.D., based in One Penumbra Place, Alameda, CA, United States, 94502, with about 4,500 employees. Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Latest reported PEN revenue for 2025-09-30 was $354.7M. Net income was $130.3M. Revenue was up 4.5% from 2025-06-30 to 2025-09-30. PEN currently screens at market cap $9.93B and trailing P/E 237.4.

Use this PEN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PEN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PEN SEC filings page. Lician reads the product cache first so this HTML stays unique to Penumbra Inc even when a live quote feed is slow.

About Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Key Statistics

Market Cap

$9.93B

Volume

3,328

Previous Close

$323.75

Day Range

$323.70$324.69

P/E Ratio

237.44

0

EPS

$0.36

Revenue

$1.19B

Net Income

$14.01M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

+319.6%

Profit Margin

1.2%

Employees

4,500

PEN Financials

Annual income statement in USD. Latest reported periods first.

PEN annual income statement across FY2024, FY2023, FY2022
LineFY2024FY2023FY2022
Revenue$1.19B$284.68M$221.22M
Cost of Revenue$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00
Net Income$14.01M$54.22M$3.88M
EPS (Diluted)$0.36$1.38$0.10

Total Assets

$1.53B

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$324.40M

Operating Cash Flow

$168.48M

Free Cash Flow

$0.00

Penumbra Inc Company Information

Co-Founder, Chairman, President & CEO
Adam Elsesser J.D.
Headquarters
One Penumbra Place, Alameda, CA, United States, 94502
Phone
510 748 3200
IPO / Founded
2015-09-18
Industry
Medical Devices
Data Updated:

Upcoming Events for PEN